Beijing Strong Biotechnologies (SZSE:300406) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Beijing Strong Biotechnologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Beijing Strong Biotechnologies is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Beijing Strong Biotechnologies's Risk Assessment

For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Strong Biotechnologies's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Beijing Strong Biotechnologies's Risk Assessment falls into.

Beijing Strong Biotechnologies (SZSE:300406) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Beijing Strong Biotechnologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Strong Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Beijing Strong Biotechnologies Inc (SZSE:300406) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 15 Hua Yuan Dong Lu, 5th Floor, Kuang Yi Building, Haidian District, Beijing, CHN, 100191

Website

http://www.bsbe.com.cn

Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.

Executives

Shuang He	Executives
Luo Ai Ping	Director
	Directors, executives
Liu Wei	Executives
Zhou Ming	Executives
Zhuang Xian Min	Directors, executives
Zhang Yi	Executives
Liu Xi	Directors, executives
Sun Xiao Lin	Director
Yu Jian Ping	Executives

Beijing Strong Biotechnologies Headlines

No Headlines